G1 Therapeutics (GTHX)
(Real Time Quote from BATS)
$7.08 USD
-0.01 (-0.14%)
Updated Aug 12, 2024 11:54 AM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 101 - 120 ( 357 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
KOL Webinar Wednesday, May 25, 2022 at 12:00 pm ET with Dr. Jared Weiss
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
1Q22 Results; Strong Cosela Sales Growth With G1''s Fully Deployed Sales Team; Data From 3 Phase 2 Trials Expected 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Cosela Primed for a Year of Commercial Execution; and Data
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
1Q22: Sequential COSELA Revenue Growth. PT $33.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
New Data Support Cosela Potential in Reducing Myelosuppression Due to Chemotherapy in Patients with ES-SCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
4Q21 Results; Cosela Sales Expected to Ramp Up in 2H22; Several Data Readouts in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
General Conference 2022: Face To Face. Synopsis of Select Companies
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
4Q21: Sequential Revenue Growth. In-House Sales Team in Effect. PT $35.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Early Data from Three Trials Slated During Second Half of This Year
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T